/
Other
Efficacy
134
Pipeline Programs↗
117
Active Trials↗
211
Companies Involved↗
Efficacy is a highly competitive landscape with 134 programs across 211 companies. The most active players are Revolution Medicines, Tango Therapeutics, Inc., ProQR Therapeutics. 30 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical52
Phase 114
Phase 238
Phase 330
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
111 of 125 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 125 classified programs, each share of the total. Modality classified for 100% of 134 pipeline programs.
Analysis
Trial Status
1,140
clinical trials
Completed746 · 65%
Unknown status136 · 12%
Terminated90 · 8%
Recruiting51 · 4%
Withdrawn45 · 4%
Not yet recruiting42 · 4%
Other30 · 3%
Clinical Trials
Trial Activity
1140 trials
A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
Recruiting·—·Phase 2·NCT06509984·20 enrolled
Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
Recruiting·—·Phase 4·NCT07342153·126 enrolled
Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety
Recruiting·—·Phase 1·NCT07453862·20 enrolled
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Recruiting·—·Phase 1·NCT06671977·60 enrolled
Warm Versus Conventional 2% Lignocaine for IANB Efficacy
Recruiting·—·Phase 2·NCT06806202·200 enrolled
Page 1 of 76
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)